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Mucosal antigens induce generation of lamina
propria plasma cells (PCs) that secrete dimeric
immunoglobulin A (IgA) destined for transport
across the epithelium. In addition, blood contains
monomeric IgA. To study the relationship between
mucosal and systemic antibody responses, we
took advantage of celiac disease patient samples
for isolation of gut PCs as well as serum IgA
and IgG reactive with a gluten-derived peptide
or the autoantigen transglutaminase 2. Proteomic
analysis of serum IgA revealed antigen-specific
V-gene preferences, which matched those found
in gut PCs. Further, gut PC CDR-H3 sequences
were abundant in serum IgA but also detectable in
serum IgG. Our data indicate that the same B cell
clones that give rise to gut PCs also contribute to
the serum antibody pool. However, serum IgA anti-
bodies had a molecular composition distinct from
that of IgA antibodies secreted in the gut, suggest-
ing that individual B cell clones give rise to different
PC populations.
INTRODUCTION
Immunoglobulin A (IgA) is the antibody isotype that is produced
in greatest quantities in the body. The majority of IgA molecules
are secreted from the vast population of plasma cells (PCs) lining
the entire gastrointestinal tract. These cells produce dimeric IgA
in which two IgA monomers are covalently linked by the joining
(J) chain. Dimeric IgA secreted in the lamina propria is trans-
ported across the epithelium via the polymeric immunoglobulin
receptor and released into the gut lumen together with a frag-
ment of the receptor known as the secretory component.
These secretory IgA antibodies bind and regulate the intestinal
microbiota and protect the epithelial barrier from pathogens
(Macpherson et al., 2008).Cell Repo
This is an open access article under the CC BY-NDifferentiation of B cells into IgA-producing PCs may be the
result of either T cell-dependent or T cell-independent activation
(Pabst et al., 2016; Spencer and Sollid, 2016). Studies carried out
in mice suggest that much of the IgA generated against gut
commensal bacteria does not rely on classical T-B collaboration
and that such antibodies often bindmultiple bacterial strainswith
low affinity (Macpherson et al., 2000; Bergqvist et al., 2006; Slack
et al., 2012). However, T cell-dependent IgA responses resulting
in high-affinity, antigen-specific antibodies can be induced in
mice by oral immunization (Lycke et al., 1987). Importantly,
in humans, the majority of antibody-producing cells in the gut
appear to be specific (Benckert et al., 2011). A prominent
example of a human condition characterized by sizeable popula-
tions of antigen-specific gut PCs is celiac disease. This gluten-
sensitive enteropathy is associated with marked changes in
the tissue architecture of the upper small bowel and infiltration
of immune cells, including large numbers of PCs, in the mucosa
(Stamnaes and Sollid, 2015). The immune reactions that lead to
formation of the celiac disease lesion are orchestrated by CD4+
T cells, which recognize certain gluten peptides in the context of
disease-associated HLA molecules. However, gluten peptides
only become T cell antigens after modification by the enzyme
transglutaminase 2 (TG2) through a process known as deamida-
tion, whereby glutamine residues are converted to glutamic acid
(Molberg et al., 1998; van de Wal et al., 1998). CD4+ T cells
recognizing deamidated gluten can provide activation signals
not only to cognate, gluten-specific B cells but also to self-reac-
tive, TG2-specific B cells, which present gluten peptides on
their surface upon internalization of TG2-gluten-B-cell receptor
(BCR) complexes (Iversen et al., 2015; Stamnaes et al., 2015;
Stamnaes and Sollid, 2015). Hence, both gluten-specific and
TG2-specific PCs can readily be detected in intestinal biopsy
specimens obtained from celiac patients (Marzari et al., 2001;
Di Niro et al., 2012; Steinsbø et al., 2014). Interestingly, the latter
specificity appears to dominate the response, and it was
shown that, on average, 10% of IgA-producing cells in the lesion
of untreated celiac disease patients are TG2 reactive (Di Niro
et al., 2012).
In addition to the IgA antibodies that are transported across
epithelial barriers, the body also contains a pool of serum IgA.rts 20, 2357–2367, September 5, 2017 ª 2017 The Author(s). 2357
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Unlike the IgA molecules that are secreted at mucosal surfaces,
serum IgA is monomeric rather than dimeric and believed to
be produced primarily by bone marrow PCs, although different
production sites are possible (Kutteh et al., 1982). Serum IgA
and IgG antibodies against deamidated gluten and TG2 are
also present in celiac disease, and because of their high disease
specificity, such antibodies have become important diagnostic
markers (Leffler and Schuppan, 2010). How these antibodies
relate to gut PCs of the same specificities is not known, although
it has been suggested that TG2-specific serum IgA ends up in
the circulation as a result of spillover from the gut production
(Marzari et al., 2001; Sollid and Lundin, 2009).
Analysis of the V-region repertoire in lymphocyte populations
comprising hundreds or thousands of clones has become
possible with the development of next-generation sequencing
(NGS) methods. Further, combining sequencing data with anal-
ysis of isolated antibodies by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) has proven to be a powerful
tool to establish connections between individual B cell clones
and secreted antibodies (Cheung et al., 2012; Lavinder et al.,
2014). Here, we apply the approach to investigate the relation-
ship between gut PCs and antibodies in serum or biopsy secre-
tions using TG2 or deamidated gluten peptide (DGP) to isolate
specific cells and antibodies from celiac patient samples.
In addition, LC-MS/MS can be applied independently to map
preferences for individual V-gene segments in specific antibody
pools (Al Kindi et al., 2016). Hence, by using purified celiac anti-
bodies, we demonstrate that important characteristics of poly-
clonal antibody responses can be obtained without the need to
interrogate PC populations.
RESULTS
Antibody Responses against Celiac Antigens Display
Isotype-Dependent Differences
In agreement with the well-established use of celiac antibodies
in diagnostic tests, we found serum IgA and IgG antibodies
targeting TG2 or DGP (peptide PLQPEQPFP) to be goodmarkers
for untreated celiac disease and readily detectable by ELISA
(Figure 1A). For the IgA antibodies, it was evident that the reac-
tivity against TG2 was higher than the reactivity against DGP,
whereas this was not the case for the IgG antibodies. When
comparing the IgA and IgG responses against each of the anti-
gens, we found a much stronger correlation for the anti-DGP
antibodies than for the anti-TG2 antibodies (Figure 1B). This dif-
ference might relate to the different nature of the antigens, as
TG2 is a tissue-bound protein autoantigen, and DGP is a soluble
peptide. Hence, DGP may distribute to different lymphoid struc-
tures in a concentration-dependent manner, whereas TG2 avail-
ability will be dictated by the expression levels in individual
tissues.
In agreement with previous observations, ELISPOT detection
of antibody-secreting cells in duodenal biopsy specimens
from celiac disease patients revealed that the number of
TG2-specific IgA PCs was higher than the number of DGP-spe-
cific cells (Figure 1C) (Steinsbø et al., 2014). There was no corre-
lation between the numbers of antigen-specific cells and the
corresponding serum IgA levels (Figure 1D), as recently reported2358 Cell Reports 20, 2357–2367, September 5, 2017for the anti-TG2 response (Di Niro et al., 2016). However, the ratio
between the numbers of TG2- and DGP-specific cells reflected
the ratio between the levels of the IgA antibodies in serum.
That is, for each patient, the observed dominance of anti-TG2
over anti-DGP IgA was equal in serum and gut samples. These
findings suggest that the serum IgA responses are tightly con-
nected to PC generation in the gut, although the gut PCs might
not be the direct source of serum antibodies. As expected,
the total number of IgG-secreting cells in the gut was much
lower than the number of IgA-secreting cells (Brandtzaeg and
Johansen, 2005), and only a few cases of antigen-specific IgG
cells could be detected (Figure 1C). Thus, it appears that the
cells secreting celiac IgG antibodies are not primarily generated
in the gut.
Serum Anti-TG2 Antibodies Primarily Target Epitopes
Known from Gut PCs
The antibody response against TG2 was previously character-
ized by generation of monoclonal antibodies (mAbs) from TG2-
specific gut PCs of celiac disease patients (Di Niro et al.,
2012). The majority of these mAbs could be placed into three
main epitope groups (epitopes 1–3), which reflected antibody
IGHV gene segment usage (Iversen et al., 2013). Notably,
epitope 1, which is recognized by antibodies using IGHV5–51,
was targeted by 30 out of 57 mAbs. Epitope mapping studies
have revealed that the epitopes are partly overlapping and
located in the N-terminal part of the TG2 protein (Figure S2A)
(Iversen et al., 2014; Chen et al., 2015). In order to test whether
the N-terminal domain of TG2 is also important for binding of
serum antibodies in celiac disease, we purified antibodies from
patient serum samples (Figure S1A–S1C) and assessed the IgA
reactivity against TG2 variants with either the N-terminal domain
replaced by the N-terminal domain of TG3 or the two C-terminal
domains missing (Figure 2A). Replacement of the N-terminal
domain reduced the reactivity of patient serum IgA dramatically,
whereas the two C-terminal domains could be removed without
great loss of reactivity. Thus, as previously found for anti-TG2
mAbs generated from gut PCs, IgA antibodies in serum primarily
target epitopes in the N-terminal part of TG2.
To further assess the overlap between epitopes targeted by
serum antibodies and mAbs generated from gut PCs, we pro-
duced three typical mAbs targeting epitope 1, 2, or 3 by recom-
binant expression in 293 cells and assessed their ability to
outcompete purified serum IgA in binding to TG2 (Figure 2B).
Importantly, the mAbs showed a similar degree of competition
between purified serum IgA and IgA secreted from PCs in gut
biopsy specimens obtained from celiac disease patients, indi-
cating that the distribution of reactivity among individual TG2
epitopes is the same for serum IgA and gut PCs (Figure 2B).
Whole serum samples rather than purified antibodies are typi-
cally used for studying TG2 reactivity. However, the use of whole
serum samples results in underestimation of the contribution of
epitope 1 specificity because of the serum content of fibronectin,
which binds to TG2 with high affinity and competes with
epitope-1-targeting antibodies for binding (Figures S1A–S2C)
(Iversen et al., 2013; Cardoso et al., 2015). Although the epitope
1 reactivity was thus partly masked, we used whole serum sam-
ples to compare epitope targeting between adult celiac disease
Figure 1. Detection of Antigen-Specific
Serum Antibodies and Gut PCs
(A) Serum antibody reactivity against TG2 or DGP
in patients with untreated celiac disease (UCD,
n = 12) or control subjects (n = 12) as determined
by ELISA. Sera were diluted 1:200 and added
to biotinylated TG2 or biotinylated DGP (biotin-
GSGSGS-PLQPEQPFP, harboring an immunodo-
minant gliadin epitope) (Schwertz et al., 2004;
Steinsbø et al., 2014) immobilized on streptavidin
followed by detection of bound IgA or IgG using
isotype-specific goat anti-human antibodies. The
dynamic range of the assay was comparable for
detection of the different antibodies. Open symbols
indicatesubjects fromwhomserumantibodieswere
purified for further characterization. The same
symbols are used throughout this study.
(B) Correlation between the levels of serum IgA
and IgG against each of the two antigens in
celiac disease patients (n = 20). Reactivity was
measured by ELISA, and the signals for each an-
tigen are given relative to the IgA signal obtained
with a reference serum sample (UCD1283).
(C) ELISPOT detection of total or antigen-specific
antibody-secreting cells (ASCs) producing IgA or
IgG in gut biopsy specimens obtained from celiac
disease patients (n = 8). Cell suspensions were
added to coated NeutrAvidin alone or NeutrAvidin
associated with biotinylated TG2 or DGP as indi-
cated. In the right panel, antigen specificity was
not considered, and only the numbers of total IgA-
or IgG-secreting cells were counted.
(D) Correlations between the number of gut ASCs
making antigen-specific IgA and the level of anti-
gen-specific IgA in serum. EC50 values represent
the serum dilution, which gives half-maximal
response in ELISA. The right panel shows the ratio
between TG2- and DGP-specific gut ASCs (x axis)
and the corresponding ratio between serum anti-
body levels (y axis). Horizontal lines indicate
means, and differences between groups were
analyzed using repeated-measures one-way
ANOVA. *p < 0.05; ***p < 0.001.patients, who are likely to have had an ongoing immune
response for extended periods of time, and childrenwith recently
developed disease. The degree of competition between anti-
TG2 mAbs and serum IgA was comparable in the two patient
groups (Figure 2C). Hence, the same main epitopes are targeted
very early in disease development and at later stages, in agree-
ment with previous observations (Simon-Vecsei et al., 2012).
SerumAntibodies against Celiac Antigens Use the Same
V-Gene Segments as Gut PCs
To further compare antigen-specific serum antibodies with the
gut immune response, we purified the TG2-reactive fractionCell Reportfrom either serum IgA or IgA secreted
from gut biopsy PCs and analyzed
TG2-binding and non-TG2-binding tryp-
sinized fractions by LC-MS/MS. Peptides
derived from antibody V-gene segmentswere identified using a database containing germline immuno-
globulin sequences supplemented with peptides identified by
de novo sequencing (Figure S3). De-novo-sequenced peptides
were included in the database if their amino acid sequence con-
tained one mismatch compared to any germline sequence. By
allowing identification of such non-germline sequences, we
were able to account for somatic hypermutation, leading to a
substantial increase in the number of peptides that could be
assigned to each V-gene segment (Table S1). Relative abun-
dances of individual V-gene segments were then determined
by summing up the peak intensities from the assigned peptides,
allowing comparison of TG2-specific and non-TG2-specifics 20, 2357–2367, September 5, 2017 2359
Figure 2. Epitope Targeting by Anti-TG2 Serum IgA
(A) Reactivity of total IgA purified from sera of celiac disease patients (n = 5) against different transglutaminase variants assessed by ELISA. In the TG3/TG2
protein, the N-terminal domain of TG2 was replaced with the N-terminal domain of TG3, whereas TG2 1–465 indicates a truncated TG2 variant lacking the two
C-terminal domains. Reactivity levels are given relative to the signals obtained with wild-type (WT) TG2 and were compared using a paired t test. *p < 0.05.
(B) Ability of individual mAbs targeting epitope 1, 2, or 3 (e1–3) to outcompete binding of purified total serum IgA to TG2. Supernatants from cultured gut biopsy
specimens obtained from celiac disease patients (n = 6) were included for comparison.
(C) Ability of the indicated mAbs to outcompete TG2-binding of IgA in whole sera of adult patients (n = 23) or children (n = 23) in whom celiac disease recently
developed. Notably, the epitope 1 mAb shows reduced competitive capacity when using whole sera instead of purified serum IgA (compare B and C). Horizontal
lines indicate means.
See also Figures S1 and S2.antibodies. Ten V-gene segments were overrepresented in the
TG2-binding IgA fraction in all five patients analyzed, and the
same preferences were observed in serum and in biopsy secre-
tions (Figure 3A; Table S2). Importantly, heavy and light chain
V-gene segments found to be overrepresented among TG2-
binding antibodies were in agreement with previous findings
based on sequencing of the antibody genes in TG2-specific gut
PCs (Di Niro et al., 2012; Snir et al., 2015; Roy et al., 2017), and
the distribution of LC-MS intensity between different IGHV fam-
ilies reflected the distribution of sequences obtained from gut
PCs of the same patient (Figure 3B). Hence, antigen-dependent
V-gene preferences can be mapped efficiently by LC-MS/MS.
IGHV5-51was theonly IGHV segment thatwasconsistently over-
represented among TG2-binding serum antibodies, reflecting a
generally strong contribution of antibodies targeting epitope 1
to the anti-TG2 pool in celiac disease. To further confirm the
connection between antigen-specific IgA in serum and gut
PCs, we repeated the analysis using purified anti-DGP serum
IgA. Also in this case, we identified an overrepresentation of
V-gene segments previously found to be used by DGP-specific
PCs, with the exception of IGHV3-23, which was not identified
because of the lack of unique peptides mapping to this V-gene
segment (Table S2) (Steinsbø et al., 2014). Collectively, these
data show that both anti-TG2 and anti-DGPserum IgA antibodies
are dominated by the same V-gene segments, which are prefer-
entially used by the corresponding gut PC populations.
Sharing of CDR-H3 Sequences between Serum
Antibodies and Gut PCs
In order to test whether antigen-specific serum antibodies are
clonally related to gut PCs, we obtained CDR-H3 sequences
from sorted TG2- or DGP-specific gut PCs and looked for2360 Cell Reports 20, 2357–2367, September 5, 2017matching amino acid sequences in affinity-purified antibody frac-
tions from the same celiac disease patients using LC-MS/MS
(Table 1; Figure S3). Antibody-derived peptide sequences
matching CDR-H3 sequences of individual TG2-specific PCs
could be detected both in serum IgA and in IgA secreted from
gut biopsy PCs. Not all PC clonotypes were detected at the anti-
body level, but they were essentially the same sequences
observed in serum and in biopsy secretions (Figure 4A;
Table S3). Typically, most of the intensity was derived from a
few prevalent clonotypes that often were represented by more
than one peptide (Tables 1 and S3). Surprisingly, serum IgA and
biopsy-derived IgA contained comparable levels of anti-TG2
CDR-H3 peptides (Figure 4B), suggesting that all gut PCs are
also represented in the serum IgA pool. Further, our data imply
that the entire anti-TG2 repertoire is contained within the small
amount of gut tissue that was collected. In support of this notion,
it was previously shown that individual biopsy specimens share a
high number of clonotypes, indicating that relatively few clonally
expanded founder cells make up the anti-TG2 repertoire in the
gut (Di Niro et al., 2016). Anti-TG2 CDR-H3 peptides were clearly
enriched in the TG2-binding fraction compared to the flow-
through fraction collected during anti-TG2 affinity purification,
confirming that the identified peptides indeed reflect TG2 speci-
ficity (Figure 4B). Likewise, enrichment of anti-DGPCDR-H3pep-
tides could be observed after affinity purification of anti-DGP
serum IgA, although the low concentration of DGP-specific IgA
in serum resulted in few detected peptides (Figure 4C; Table S4).
Serum IgG Exhibits Weaker Clonal Relatedness to Gut
PCs than Serum IgA
Unlike purification of total serum IgA, purification of total
serum IgG was associated with accumulation of low-affinity
Figure 3. Bias in V-Gene Segments Used by
Anti-TG2 IgA Antibodies
(A) Volcano plot showing differences in the use of
V-gene segments between affinity-purified anti-
TG2 IgA and non-TG2-specific IgA (flow-through
fraction) obtained from serum or gut biopsies of a
representative celiac disease patient (UCD1317).
Functional V-gene segments were identified based
on matching of MS/MS spectra to amino acid
sequences obtained from http://www.imgt.org,
resulting in detection of unique peptides for 80%
of the database V-gene segments. The amounts of
individual V-gene segments in each sample were
quantified using MaxQuant software (Cox and
Mann, 2008). V-gene segments significantly more
abundant in the TG2-specific fraction are indicated
with blue symbols, whereas V-gene segments of
lower abundance are shown in red (p < 0.05).
V-gene segments overrepresented among TG2-
specific serum IgA in all five patients analyzed are
indicated with their names, and names shown in
bold indicate V-gene segments, which were
previously found to be used by TG2-specific gut
PCs (Di Niro et al., 2012; Snir et al., 2015; Roy
et al., 2017).
(B) Distribution of antibodies and PCs among
different IGHV families in UCD1317. The distribu-
tion of TG2-specific and non-TG2-specific gut PCs
is based on the numbers of unique sequences
obtained byNGS,whereas the distribution of affinity-purified anti-TG2 or flow-through IgA isolated from serumor gut biopsy specimens is based on IGHV peptide
LC-MS intensities obtained as intensity-based absolute quantification (iBAQ) values in MaxQuant. Error bars represent SD based on triplicate LC-MS/MS runs.
See also Figure S3 and Tables S1 and S2.TG2-binding antibodies, which did not bind the antigen in whole
serum andwere not related to celiac disease (Figures S1A–S1C).
Hence, the TG2-specific IgG fraction could not be isolated and
analyzed after initial purification of total IgG in a way similar to
that described above for the IgA antibodies. However, when
TG2-binding antibodies were isolated from whole serum without
initial separation into total IgA and IgG preparations, we were
able to detect IgG-derived anti-TG2 CDR-H3 peptides in the
fraction eluted from TG2 based on the sequence of constant-re-
gion amino acids following the CDR-H3 region (Figure 5A;
Table S5). Thus, anti-TG2 CDR-H3 sequences obtained from
gut PCs are represented among both serum IgA and serum
IgG and are detectable after purification of TG2-binding mole-
cules from whole serum samples. However, sequences shared
with gut PCs seemed to be less frequent in anti-TG2 IgG than
in anti-TG2 IgA (Figure 5B), and most of the detected anti-TG2
CDR-H3 peptides were different for the two antibody classes
(Figure 5C). Thus, there exist serum IgA and IgG antibodies
that are clonally related to gut PCs, but the connection is stron-
ger for IgA than for IgG.
Serum andGut Anti-TG2 IgADisplay DifferentMolecular
Compositions
To get an indication of the cellular origin of antigen-specific
serum IgA in celiac disease, we assessed the distribution
between monomeric and dimeric forms in TG2-specific IgA pu-
rified from celiac patient serum or gut biopsy secretions. The
TG2-specific IgA fractions appeared similar to the total IgA prep-
arations, with antibodies purified from serum being mostlymonomeric and antibodies purified from biopsy specimens be-
ing dimeric (Figure 6A).
The relative abundances of individual proteins in a sample can
be approximated from the peptide intensities of extracted-ion
chromatograms (Figures 3B and S4A). Thus, to obtain further
insight into the molecular composition of different IgA fractions,
we quantified the levels of J chain and the distribution of IgAmol-
ecules between the IgA1 and IgA2 subclasses (Figure 6B). In
agreement with the observed distributions between monomers
and dimers, gut biopsy IgA contained higher levels of J chain
than serum IgA. However, TG2-specific serum IgA seemed to
be associated with more J chain than the non-TG2-specific
serum fraction. As expected, both serum IgA and IgA secreted
from duodenal biopsy specimens consisted mostly of IgA1 (Fig-
ure 6B) (Brandtzaeg and Johansen, 2005). Both in serum and in
biopsy secretions, the TG2-specific fraction contained even
lower levels of IgA2 than the non-TG2-specific fraction, but while
IgA2 still made up an estimated 5%–10% of TG2-specific IgA in
the gut, this subclass was virtually absent in the TG2-specific
serum IgA fraction. Collectively, these data demonstrate that
the TG2-specific IgA antibodies present in serum and gut biopsy
secretions have different molecular compositions, suggesting
that the majority of anti-TG2 serum antibodies are not produced
by gut PCs, although some J-chain-containing IgA dimers
generated in the gut might end up in the circulation, either by
escaping transport across the epithelium or via retrotransport
from the gut lumen mediated by binding of secretory IgA to
CD71 on the apical surface of epithelial cells (Lebreton et al.,
2012). In support of the latter mechanism, we did detect lowCell Reports 20, 2357–2367, September 5, 2017 2361
Table 1. Detection of CDR-H3 Sequences from Antigen-Specific Gut PCs in Affinity-Purified Serum or Gut IgA by LC-MS/MS
NGS: Gut PCs LC-MS/MS: Serum or Gut IgAa
No. of PCs
No. of
Sequences
Unique CDR-H3
Sequences Clonotypesb
CDR-H3 Peptides
Detected Clonotypes
Top Clonotype
Intensity (%)c
Anti-TG2
UCD1279 1,100 1,217 466 364 27/20 26/20 15/14
UCD1283 2,500 2,561 573 340 83 53 18
UCD1287 2,500 7,137 1,324 741 99 75 43
UCD1317 970 1,305 253 121 49/60 35/36 54/38
Anti-DGP
UCD1283 1,300 274 140 134 7 4 73
UCD1287 550 753 164 132 5 3 67
LC-MS/MS, liquid chromatography-tandem mass spectrometry; NGS, next-generation sequencing; PCs, plasma cells.
See also Figure S3 and Tables S3 and S4.
aNumbers reflect CDR-H3 peptides identified in serum IgA. When two numbers are given, they indicate peptides identified in serum/biopsy
supernatant.
bSequences assigned to the same clonotype use the same IGHV and IGHJ gene segments and haveR85% sequence identity in the CDR-H3 region
(Tipton et al., 2015).
cThe LC-MS intensity of the highest-intensity clonotype is given relative to the total LC-MS intensity of all identified CDR-H3 peptides in the sample.amounts of the polymeric immunoglobulin receptor among
serum antibodies eluted from TG2 by LC-MS/MS (Figure S4B).
Notably, the IgA response against TG2 is skewed toward
production of IgA1, and the PCs responsible for secretion of
serum anti-TG2 IgA seem to be recruited almost exclusively
from IgA1-expressing cells. Likewise, we observed a biased
distribution of anti-TG2 serum IgG in favor of the IgG1 subclass
(Figure S4C).
DISCUSSION
The relationship between mucosal and systemic immune re-
sponses is not well understood, and the origin of circulating
antibodies against gut antigens has not previously been investi-
gated thoroughly. In this study, we have characterized the
antibody response against two antigens, TG2 and DGP, in
celiac disease patients. Both responses are dependent on a
gluten-containing diet and are associated with accumulation of
antigen-specific PCs in the gut lesion. Strikingly, serum IgA
antibodies targeted the same epitopes and used the same
preferred V-gene segments as the gut PCs. Moreover, detection
of antigen-specific CDR-H3 regions showed that serum
antibodies and gut PCs are clonally related. Analogous to
what has recently been observed for vaccine-elicited anti-flu
antibodies (Lee et al., 2016) and anti-desmoglein autoantibodies
(Chen et al., 2017), we found that relatively few clonotypes
contributed most of the serum LC-MS intensity that could be
ascribed to anti-TG2 CDR-H3 peptides. These clonotypes also
represented some of the most abundant gut PCs, as judged by
the number of sequenced transcripts, thus underscoring the
tight connection between serum and gut IgA.
Despite the strong clonal relatedness between serum anti-
bodies and gut PCs, we found anti-TG2 serum IgA to be mostly
monomeric, whereas anti-TG2 antibodies secreted by gut PCs
were J-chain-associated dimers and contained a larger fraction
of the IgA2 subclass. Similar molecular differences have also2362 Cell Reports 20, 2357–2367, September 5, 2017been described for gluten-specific serum and gut IgA in celiac
disease (Volta et al., 1990). Together with the lack of correlation
between gut PC numbers and serum antibody levels, these find-
ings suggest that gut PCs are not the direct source of the specific
serum IgA antibodies.
Independent regulation of IgA responses in gut and serum has
previously been observed in CD28-deficient mice (Ga¨rdby et al.,
2003). Our data are in agreement with this concept but at the
same time strongly suggest that serum antibodies and gut PCs
originate from the same B cell clones. In line with this model,
IgA-expressing cells derived from mucosal immune responses
are present in human blood and in bone marrow during steady-
state conditions (Mei et al., 2009). Further, it was recently shown
that antigen-specific, clonally relatedPCs are present in the bone
marrow and gut after oral immunization of mice (Bemark et al.,
2016; Lemke et al., 2016). Hence, together with previous studies,
the data presented here contend that B cells activated in the gut
immune system give rise to PCs that reside in the lamina propria
and produce dimeric IgA for transport across the epithelium as
well as an equivalent population of PCs that migrate to the
bone marrow and secrete monomeric IgA into the circulation.
We observed that CDR-H3 sequences obtained from TG2-
specific gut PCs were represented both in the IgA fraction and
in the IgG fraction of TG2-binding serum antibodies. In agree-
ment with this finding, sharing of V-region sequences between
TG2-specific gut PCs and IgG memory cells was previously
demonstrated in celiac disease (Snir et al., 2015). Additionally,
clonally related IgA and IgG PCs could be detected in orally
immunized mice (Bemark et al., 2016). Thus, single B cells can
give rise to both IgA- and IgG-expressing cells. However,
compared to IgA antibodies, anti-TG2 IgG displayed a lower
frequency of CDR-H3 sequences that were shared with gut
PCs. One explanation for this observation could be that IgA-
and IgG-expressing cells, despite being clonally related, acquire
different V-region mutations and therefore tend to differ in their
CDR-H3 sequences, as recently shown for B cell clonotypes
Figure 4. Sharing of CDR-H3 Sequences be-
tween Purified IgA Fractions and Gut PCs
(A) Matching between peptide sequences obtained
from affinity-purified anti-TG2 IgA and CDR-H3
sequences of TG2-specific IgA gut PCs. Antibodies
were isolated from serum or gut biopsy specimens,
and peptides containing all or part of a CDR-H3
region were identified by LC-MS/MS based on
matching to a database of CDR-H3 sequences
obtained from TG2-specific gut PCs of the same
celiac disease patient (UCD1317) by NGS. Se-
quences from PCs were grouped into clonotypes,
which were ranked from 1 to 121 according to
decreasing numbers of sequenced transcripts (i.e.,
clonotype 1 was associated with the highest num-
ber of immunoglobulin mRNA molecules). Bars
show the summed LC-MS intensities of peptides
matching individual clonotypes as a percentage of
the total anti-TG2CDR-H3 peptide intensity of each
sample. Hence, each bar represents detection
of a particular clonotype at the antibody level. The
data are representative of four analyzed patients
(summarized in Table 1).
(B) Quantification of the amount of antibodies con-
taining CDR-H3 regions matching sequences of
TG2-specific gut PCs in affinity-purified anti-TG2
antibodies or the TG2 flow-through (FT) fraction of
celiac disease patient samples. TG2-binding and
non-TG2-binding fractions were isolated from puri-
fied total IgA of sera or gut biopsy specimens. The
normalized level of anti-TG2CDR-H3 regions ineach
sample (the anti-TG2 CDR-H3 index) was deter-
mined by dividing the number of identified peptides
containing TG2-specific CDR-H3 sequences with
the number of all CDR-H3-containing peptides that
could be identified by de novo peptide sequencing.
(C) Detection of peptides matching CDR-H3 sequences obtained from DGP-specific gut PCs in anti-DGP or DGP FT IgA isolated from purified total serum IgA of
two celiac disease patients. Because of the low concentration of DGP-specific IgA, CDR-H3 indices could not be calculated, as was done for the TG2-specific
antibodies. Horizontal lines indicate means.
See also Figure S3 and Tables S3 and S4.comprising cells of different immunoglobulin classes (Horns
et al., 2016). Alternatively, many of the TG2-specific IgG PCs
are generated from a separate population of B cell clones,
possibly at other anatomical locations. Such a distinction might
explain why anti-TG2 IgG is generally a poorer diagnostic marker
than anti-TG2 IgA (Leffler and Schuppan, 2010).
Immune reactions involving gluten might occur at sites distant
from the gut, as exemplified by the conditions dermatitis herpeti-
formis and gluten ataxia, which can be considered extraintestinal
manifestations of celiac disease affecting the skin and brain,
respectively. Relevant to these clinical observations, gluten-
derived peptides can be detected in urine following gluten
consumption, demonstrating that antigenic peptides are system-
icallydistributed (Morenoetal., 2017). Theobserved tight connec-
tion between serum levels of anti-DGP IgA and IgG might reflect
the presence of gluten peptides both in the gut and in the circula-
tion, asmucosal immune responses primarily give rise to IgA pro-
duction while systemic responses are dominated by IgG (Mei
et al., 2009). Thus, the IgA response could be initiated in Peyer’s
patches or mesenteric lymph nodes, whereas the spleen might
also contribute to IgG induction. The anti-TG2 response, on the
other hand, did not show the same strong correlation betweenIgA and IgG levels. Although this response is also dependent
on availability of gluten peptides, it should also reflect the TG2
expression and activity levels, which may vary between different
tissues. Thus, if anti-TG2 IgA and IgG mainly originate from
different B cell populations at different anatomical sites, the local
levels of available, active TG2 enzyme might control the relative
contribution of the two isotypes to the serum antibody pool.
In conclusion, by using a combination of NGS and LC-
MS/MS, we have shown that there is a close relationship
between PCs in the gut and serum IgA antibodies against
two different antigens in celiac disease patients. Although the
gut PCs do not seem to produce the antibodies present in
serum, a high level of shared CDR-H3 sequences implies that
serum IgA and gut PCs are clonally related. Gut PC CDR-H3
sequences could also be detected in serum IgG, indicating
that B cell clones activated in the mucosal immune system
contribute to the serum IgG pool. In addition, we demonstrate
the use of LC-MS/MS alone to obtain characteristics of affinity-
purified antibodies, including V-gene preferences and subclass
distributions. This analysis can be useful for assessing the
composition of antibody responses against various antigens
and requires only a serum sample.Cell Reports 20, 2357–2367, September 5, 2017 2363
Figure 5. Detection of PC CDR-H3 Se-
quences in Anti-TG2 IgA and IgG Isolated
from Whole Sera
(A) Quantification of the amount of antibodies
with CDR-H3 regions matching sequences of TG2-
specific gut PCs among affinity-purified anti-TG2 or
TG2flow-through (FT) IgGobtained fromwhole sera
of three celiac disease patients. The anti-TG2 CDR-
H3 levels are determined as CDR-H3 indices as
shown in Figure 4B.Horizontal lines indicatemeans.
(B) Comparison of the level of anti-TG2 CDR-H3
peptides derived from IgA or IgG after isolation
of TG2-binding antibodies from whole serum sam-
ples.Connecting lines indicate detection of IgA- and
IgG-derived CDR-H3 peptides in the same sample.
The anti-TG2 CDR-H3 levels were compared using
a paired t test. **p < 0.01.
(C) Venn diagrams showing overlap between anti-
TG2 CDR-H3 peptides detected in affinity-purified
anti-TG2 IgA or IgG obtained from whole serum
or from purified total serum IgA of three celiac dis-
ease patients. Numbers indicate identified peptides
containing CDR-H3 regions matching sequences
obtained from TG2-specific gut PCs of the same
patient. Area-proportional ellipses were generated
using eulerAPE (Micallef and Rodgers, 2014).
See also Figure S1 and Table S5.EXPERIMENTAL PROCEDURES
Human Samples
Blood and/or duodenal biopsy specimens were collected from 32 adult celiac
disease patients and 12 control subjects who had given their informed con-
sent. Ethical approval was given by the Regional Ethics Committee of
South-Eastern Norway (project 2010/2472), and the diagnosis of celiac
disease was given according to the recent guidelines of the British Society
of Gastroenterology (Ludvigsson et al., 2014). In addition, 23 serum samples
of young children (median age 2.8 years, range 1.9–5 years) with newly diag-
nosed celiac diseasewere included from the Hungarian participants in the Pre-
ventCD project (http://www.preventceliacdisease.com), a prospective FP6
European multicenter study following at-risk infants from celiac families after
randomized gluten introduction at 4 or 6 months of age. Blood was collected
upon informed consent from the parents 7 times until 3 years of age and then
annually. Ethical approval was given by the ethics committees of all partici-
pating centers, including that of Heim Pa´l Children’s Hospital (Budapest,
Hungary). Unless otherwise stated, the analyzed samples were from adult
celiac disease patients. Biopsy specimens (6–12 from each patient) were dis-
rupted by incubation with 1 mg/mL collagenase (Sigma) in 2% (v/v) fetal calf
serum (FCS)/PBS under constant rotation for 1 hr at 37C. The digested sam-
ple was homogenized with a syringe and filtered through a 40-mm cell strainer.
The obtained single-cell suspension was either used directly or cultured for
2–4 weeks in 10% (v/v) FCS/RPMI-1640 together with human intestinal fibro-
blasts as previously described (Steinsbø et al., 2014) prior to staining and
fluorescence-activated cell sorting (FACS) of PCs. Supernatants from cultured
biopsy specimens were collected for isolation of secreted antibodies.
Recombinant Proteins
Recombinant human TG2 (Phadia) and TG3 (Zedira) produced in insect cells
were used to assess antibody binding to the wild-type proteins by direct2364 Cell Reports 20, 2357–2367, September 5, 2017coating in ELISA as described in Supplemental
Experimental Procedures. Proteins produced in
Escherichia coli were used for comparison of wild-
type TG2 and variants without the two C-terminal
domains (residues 1–465) (Iversen et al., 2013) orwith theN-terminal domain replacedby theN-terminal domain of TG3 (residues
1–136 from TG3 and residues 141–687 from TG2) (Cardoso et al., 2017). For
attachment to streptavidin or NeutrAvidin, we used TG2 produced in E. coli
with anN-terminal BirA biotinylation sequence (Hnida et al., 2016). Site-specific
biotinylation was carried out with the BirA biotin-protein ligase (Avidity) accord-
ing to the instructions provided by the manufacturer. Anti-TG2 mAbs targeting
different epitopeswere expressed as human IgG1molecules inHEK293-F cells
and purified on protein G (GE Healthcare) as previously described (Chen et al.,
2015). The Jo-1 antigen was obtained from Phadia.
LC-MS/MS Sample Preparation
Antigen-specific antibodies were purified from serum or supernatants of
cultured gut biopsies as described in Supplemental Experimental Procedures.
The eluate and flow-through fractions were dried under vacuum followed
by resuspension in 50 mL 50 mM NH4HCO3, 8 M urea. The antibodies were
reduced with 10 mMDTT for 1 hr at 60C followed by alkylation with 30mM io-
doacetamide for 1 hr at room temperature. The samples were then diluted with
150 mL 50 mM NH4HCO3 before overnight digestion with Sequencing Grade
Trypsin (Promega) at 37C, using a trypsin/antibody ratio of 1:50 (w/w). The re-
actionwasquenchedby addition of trifluoracetic acid to a final concentration of
1% (v/v). Peptideswere cleanedprior to LC injection by theSTAGE-TIPmethod
(Rappsilber et al., 2003) using a C18 resin disk (3M Empore). Sample analyses
were basedonduplicate or triplicate runs using anEasy nLC1000nano-LC sys-
tem connected to a quadrupole Orbitrap (Q Exactive) mass spectrometer
(ThermoElectron) equipped with a nanoelectrospray ion source (EasySpray/
Thermo) as detailed in Supplemental Experimental Procedures.
Database Generation
In order to increase identification coverage of antibody V-gene segments, we
used a de novo approach to include mutations in the reference germline data-
base, which contained amino acid sequences of all human V-gene segments
Figure 6. Composition of IgA Fractions Ob-
tained from Sera or Gut Biopsy Specimens
(A) Western blot showing detection of monomeric
and dimeric forms of purified total or TG2-specific
IgA obtained from serum or gut biopsies of a celiac
disease patient (UCD1317). The appearance of
anti-TG2 serum IgA is representative of five
analyzed patients.
(B) LC-MS/MS quantification of the amount of
J chain and IgA2 subclass in the TG2-specific or
TG2 flow-through (FT) fractions of total IgA in sera
or gut biopsy specimens obtained from two celiac
disease patients. Quantification is based on iBAQ
values obtained with MaxQuant and is given rela-
tive to the summed iBAQ values of the IgA1 and
IgA2 constant regions in each sample. Themethod
overestimates the amount of J chain somewhat,
as a dimeric IgA molecule consists of four IgA
heavy chains and one J chain, giving a maximum
J chain/IgA molar ratio of 0.25. Error bars repre-
sent SD based on duplicate (UCD1279) or tripli-
cate (UCD1317) LC-MS/MS runs.
See also Figure S4.obtained from the International ImMunoGeneTics Information System (IMGT)
database (Lefranc et al., 1999). By using the germline database for proper
sequence alignment, peptides carrying single amino acid substitutions were
identified and added to the database as detailed in Supplemental Experi-
mental Procedures.
Identification of CDR-H3 Peptides
For identification of CDR-H3 sequences obtained by NGS at the protein level, a
database of complete tryptic peptides containing CDR-H3 sequences was
built for each patient by adding the last six J-segment amino acids and the
beginning of the constant region (ASTK for IgG and ASPTSPK for IgA) to the
antibody sequences. Matching peptides from antigen-specific and non-spe-
cific antibody fractions were then identified by LC-MS/MS. In addition to
CDR-H3 amino acids, all analyzed CDR-H3 peptides contained the conserved
J-segment and constant-region sequences, and some peptides might there-
fore have been too long for detection. However, many CDR-H3 regions con-
tained internal tryptic cleavage sites, resulting in shorter peptides harboring
only part of the CDR-H3 region (see Tables S3, S4, and S5 for the complete
list of identified CDR-H3 peptides). In order to normalize the number of
database CDR-H3 peptides that could be detected in a sample, we used de
novo sequencing to identify peptides harboring CDR-H3 regions of any spec-
ificity, characterized as amino acid sequences ending in ASTK (IgG) or
ASPTSPK (IgA).
Sequencing of Antigen-Specific PCs
Antigen-specific IgA PCs in gut biopsy specimens were FACS sorted and their
heavy chain V regions sequenced using Illumina MiSeq as detailed in Supple-
mental Experimental Procedures. IGHV, IGHJ, and CDR-H3 were assigned
using IMGT, and clonal relatedness between sequences was established
based on matching IGHV and IGHJ gene segments, identical CDR-H3
length, and R85% sequence identity throughout the CDR-H3 region (Tipton
et al., 2015).
ELISPOT
MultiScreen 96-well filter plates (Millipore) were coated with 5 mg/mL
NeutrAvidin (Thermo) or goat anti-human Ig (Southern Biotech) in PBS. The
wells were washed with PBS and blocked with 1% (w/v) BSA/PBS before bio-
tinylated TG2 (5 mg/mL) or biotinylated DGP (100 nM) was added to coated
NeutrAvidin. After washing with PBS, various dilutions of gut biopsy single-
cell suspensions were added to the wells in 10% (v/v) FCS/RPMI and incu-bated overnight at 37C in a CO2 incubator. The cell suspensions were dis-
carded, and the wells were washed with PBS and PBS containing 0.1% (v/v)
Tween 20 (PBST). Bound IgA or IgG was detected by incubation with alka-
line-phosphatase-conjugated goat anti-human IgA or goat anti-human IgG
in 1% (w/v) BSA/PBST followed by washing and addition of BCIP/NBT sub-
strate (Bio-Rad). Spots were counted using an ImmunoSpot analyzer (Cellular
Technology Limited).
Western Blotting
Purified TG2-specific or total IgA samples were boiled in non-reducing SDS-
PAGE sample buffer and separated on a 4%–20% TGX gel (Bio-Rad). Proteins
were blotted onto nitrocellulose, and the membrane was blocked in 2% (w/v)
skim milk/PBS. IgA was detected using rabbit anti-human IgA (Dako)
followed by horseradish-peroxidase-conjugated goat anti-rabbit IgG (South-
ern Biotech).
Statistics
Data are presented as mean ± SD and analyzed using GraphPad Prism soft-
ware, unless otherwise stated. Differences between groups were analyzed
using one-way ANOVA or Student’s t test, and scatterplots were analyzed
by Pearson correlation analysis. A p value of <0.05 was considered significant.
ACCESSION NUMBERS
The accession numbers for the raw mass spectrometry data and antibody se-
quences used for creating search databases are MassIVE: MSV000081328
(http://massive.ucsd.edu) and ProteomeXchange: PXD007047.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.08.036.
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Figure S1. Assessment of purified anti-TG2 IgA or IgG reactivity by ELISA. Related to Figures 2 and 5 
 
 
 
(A) Total IgA or IgG purified from celiac disease patient or control sera or from supernatants of cultured gut biopsies 
were incubated in TG2-coated microtiter plates in the presence or absence of fibronectin (Fn, 5 µg/ml in the highest 
concentration). Whole sera or culture supernatants were added in corresponding dilutions for comparison, and bound 
IgA or IgG was detected using isotype-specific goat anti-human antibodies. Supplementation of purified antibodies 
with Fn decreases their TG2 reactivity and make them mimic the behavior of whole sera, indicating that binding 
between TG2 and serum Fn blocks a substantial number of antibody binding sites. For the control subject, TG2 
reactivity is present in the purified IgG fraction but not in whole serum or in purified IgA, indicating that purification 
of IgG alters the binding properties of some antibody molecules . The reason for this behavior of IgG is most likely 
that exposure to low pH during purification alters the structure of some IgG molecules, allowing them to interact 
with new antigens (Dimitrov et al., 2013). 
(B) Binding of affinity-purified anti-TG2 antibodies isolated from total serum IgA or IgG preparations. Histidyl 
tRNA synthetase (Jo-1) was included as an irrelevant antigen to test the specificity of the purified antibodies. In all 
cases, the purified IgG antibodies have lower apparent affinity than the IgA antibodies. Notably, TG2-binding IgG, 
but not IgA, could be isolated from non-celiac control serum, but these antibodies had very low affinity.  
(C) TG2 binding of affinity-purified IgA and IgG isolated from whole sera without initial separation into total IgA 
and IgG fractions. When purifying the TG2-binding fraction from whole sera, there is no clear difference between 
IgA and IgG affinities. 
  
Figure S2. Reactivity of antibodies with different regions of TG2 assessed by ELISA. Related to Figure 2 
 
 
 
(A) Saturation binding curves for anti-TG2 mAbs targeting different epitopes to TG2 domain variants as determined 
by ELISA. All three mAbs lose reactivity when the N-terminal domain of TG2 is replaced with the N-terminal 
domain of TG3 (TG3/TG2) but show intact reactivity when the two C-terminal domains are removed (TG2 1-465).  
(B) Reactivity of IgA in whole serum samples from adult celiac disease patients (n = 23) with TG2 domain variants 
as shown for purified serum IgA in Figure 2A. No reactivity was observed against full-length TG3, indicating that 
binding observed with TG3/TG2 is mediated solely by TG2 epitopes located outside of the N-terminal domain.  
(C) Ability of the indicated anti-TG2 mAbs to compete with serum IgA for TG2 binding in the presence of added 
fibronectin (Fn, 1 µg/ml). Total serum IgA was purified from celiac disease patients (n = 5), and the reactivity is 
given relative to the signal obtained in the absence of mAbs but with added Fn. In the presence of Fn, addition of 
epitope-1 mAb does not have an effect on binding of serum IgA (compare with Figure 2B). Horizontal lines indicate 
means. 
  
Figure S3. Overview of the quantitative proteomics approach and software used for antibody analysis. 
Related to Table 1 and Figures 3 and 4 
 
 
 
Antigen-specific antibodies were either isolated from cultured gut biopsies or serum samples of celiac disease 
patients and analyzed by LC-MS/MS. Peptides derived from V-gene segments and CDR-H3 were identified by two 
separate procedures. Heavy and light chain V-gene peptides were identified using a database consisting of germline 
amino acid sequences combined with mutated peptides discovered by de novo MS sequencing. In order to identify 
CDR-H3 peptides, antigen-specific PCs were sorted from gut biopsies, and heavy chain V-region sequences were 
obtained by NGS. 
  
Figure S4. Quantification of antibody class distributions by LC-MS/MS. Related to Figure 6 
 
 
 
(A) The ratio between IgA and IgG antibodies was determined based on iBAQ values obtained with MaxQuant 
software in affinity-purified anti-TG2 or TG2 flow-through (FT) fractions obtained from whole sera of three celiac 
disease patients. For the TG2-binding fraction (left panel), the IgA:IgG ratio determined by LC-MS/MS (y-axis) was 
compared to the ratio obtained by measuring the IgA and IgG concentrations by ELISA (x-axis). At higher IgA:IgG 
ratios, the LC-MS/MS method appears to overestimate the contribution of IgG. The ratios obtained from the TG2 FT 
fractions (right panel) are within the expected range (Gonzalez-Quintela et al., 2008). Error bars indicate SD based 
on duplicate LC-MS/MS runs.  
(B) Quantification of the amount of polymeric Ig receptor (pIgR) associated with the TG2-binding or TG2 FT 
fractions of purified total IgA from sera or gut biopsies of two celiac disease patients. The quan tification is based on 
iBAQ values and is given relative to the summed iBAQ values of the IgA1 and IgA2 constant regions in each sample . 
This ratio should give an indication of the contribution of secretory IgA to each population . Error bars represent SD 
based on duplicate (UCD1279) or triplicate (UCD1317) LC-MS/MS runs. 
(C) The distribution of IgG between individual subclasses based on iBAQ values measured in affinity -purified anti-
TG2 and TG2 FT fractions obtained from whole sera of celiac disease patients. In all cases, the IgG1 subclass is 
overrepresented among TG2-specific antibodies compared to the TG2 FT fraction. 
  
Table S1. Identification of Ig proteins in affinity-purified gut biopsy anti-TG2 and TG2 flow-through IgA of a 
representative celiac disease patient (UCD1317) by LC-MS/MS. Related to Figure 3 
 
 Anti-TG2  TG2 flow-through 
 Germline only 
Germline +  
de novo 
 
Germline only 
Germline +  
de novo 
Protein groups identified
a 
121 147  116 144 
Proteins per group (avg.) 2.72 2.35  2.91 2.36 
Peptides per group (avg.) 4.03 41.4  3.55 48.2 
Unique peptides per 
group (avg.) 
1.73 5.57 
 
1.82 6.75 
 
a
 Each protein group comprises all proteins in the database that share the same identified peptides. The germline only 
database contains all Ig V-gene segments and constant regions available from http://www.imgt.org. Entries in this 
database were supplemented with peptide sequences harboring single-amino acid substitutions identified by de novo 
sequencing to obtain the germline + de novo database. Typically, individual alleles could not be distinguished and 
were placed in the same protein group, whereas different V-gene segments often could be separated. Due to the large 
degree of similarity between V-gene segments, many peptides were shared between groups, but each group is 
represented by at least one unique peptide. 
  
Table S2. List of V-gene segments overrepresented among purified anti-TG2 or anti-DGP serum IgA of celiac 
disease patients. Related to Figure 3 
 
 
Anti-TG2
a 
 
Anti-DGP
a 
 
5 of 5 
patients 
4 of 5 
patients  
2 of 2 
patients 
IGHV1-69 
 
X 
  
IGHV3-7 
 
X 
 
X 
IGHV3-15 
   
X 
IGHV3-30 
   
X 
IGHV3-43 
 
X 
  
IGHV3-74 
   
X 
IGHV5-51 X 
   
     IGKV1-5 X 
   
IGKV1-12 X 
   
IGKV1-16 
 
X 
  
IGKV1-17 X 
   
IGKV1-27 
 
X 
  
IGKV1-39 X 
   
IGKV3-20 X 
   
IGKV4-1 
   
X 
     IGLV1-44 X 
   
IGLV1-47 X 
   
IGLV2-11 
 
X 
  
IGLV2-14 X 
   
IGLV4-69 
   
X 
IGLV5-45 X 
   
 
a
 V-gene segments that were significantly more abundant in antigen-specific compared to non-specific serum IgA 
fractions across celiac disease patients are indicated. Symbols in bold indicate V-gene segments previously found to 
be used by TG2-specific (Di Niro et al., 2012; Snir et al., 2015; Roy et al., 2017) and DGP-specific (Steinsbø et al., 
2014) gut PCs. 
 
  
Table S3. Anti-TG2 CDR-H3 peptides detected by LC-MS/MS in affinity-purified anti-TG2 or flow-through 
fractions isolated from IgA of serum or gut biopsy secretions. Related to Figure 4 and Table 1. 
See Excel file 
 
Table S4. Anti-DGP CDR-H3 peptides detected by LC-MS/MS in affinity-purified anti-DGP or flow-through 
fractions isolated from serum IgA. Related to Figure 4 and Table 1. 
See Excel file 
 
Table S5. Anti-TG2 CDR-H3 peptides detected by LC-MS/MS in affinity-purified anti-TG2 or flow-through 
fractions isolated from whole sera. Related to Figure 5. 
See Excel file 
 
 
 
  
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
ELISAs. Recombinant human proteins were coated in microtiter plates at 3 µg/ml in TBS. For comparison of TG2 
and DGP reactivity, biotinylated TG2 (1 µg/ml) or biotinylated DGP (biotin-GSGSGS-PLQPEQPFP, obtained from 
GL Biochem, 50 nM) was attached to streptavidin-coated plates (Thermo) in TBS containing 0.1% (v/v) Tween 20 
(TBST). For comparison of reactivity to different TG2 variants, the enzymes were associated with the irreversible 
inhibitor Ac-P(DON)LPF-NH2 (Zedira) to ensure that they had equal and homogenous conformations prior to 
coating (Iversen et al., 2014). To this end, the TG2 variants were incubated with 0.5 mM of the inhibitor for 20 min 
at room temperature before the reaction was started by addition of CaCl2 to a final concentration of 5 mM and further 
incubation for 30 min. Incubation with antibodies were carried out at 37C in 3% (w/v) BSA/TBST followed by 
detection of bound IgA or IgG using alkaline phosphatase-conjugated goat anti-human IgA (Sigma) or goat anti-
human IgG (Southern Biotech). To compare antibody reactivity against different TG2 variants or in the presence or 
absence of competitor, initial titration of all sera or purified antibodies was carried out, and a concentration falling 
within the linear range of the reference assay (using wild-type TG2 in the absence of competitor) was in each case 
picked for determination of relative binding levels based on changes in OD value. Competition between polyclonal 
antibodies and anti-TG2 mAbs was assessed by incubating coated TG2 with 10 µg/ml anti-TG2 IgG1 mAbs for 30 
min at 37C, before polyclonal antibody preparations were added without removing the mAbs, and incubation was 
continued for 1 h. The level of bound polyclonal IgA was subsequently detected as above. Concentrations of IgA and 
IgG in TG2-binding fractions purified from whole sera were determined by incubation with goat anti-human IgA 
(Sigma) or rabbit anti-human IgG (Dako), each coated at 5 µg/ml, and detection of bound antibodies using alkaline 
phosphatase-conjugated goat anti-human IgA or rabbit anti-human IgG (Abcam). Obtained signals were compared to 
a standard curve obtained using purified total serum IgA or IgG. 
 
Antibody purification. Total IgG was purified from 20 ml of serum or plasma by diluting the sample in 20 mM 
NaPi, pH 7.4 and passing it over a protein G column (GE Healthcare). Bound IgG was eluted with 0.1 M glycine -
HCl, pH 2.5 and immediately neutralized with 1 M Tris -HCl, pH 9. IgA was purified from the protein G flow-
through fraction using peptide M-agarose (Invivogen) followed by elution of bound IgA as described for purification 
of IgG. IgA secreted from duodenal biopsies was purified from culture supernatants in the same way. To isolate 
TG2-binding IgA and IgG, we mixed up to 10 ml of purified antibodies or 1 ml of whole serum diluted ten times in 
TBS with 400 µl 50% (v/v) streptavidin-agarose (Novagen) that had been pre-associated with 100 µg biotinylated 
TG2 in a Poly-Prep chromatography column (Bio-Rad), followed by incubation for 1 h under constant rotation at 
room temperature. A new column with fresh TG2 protein was prepared for each sample. The flow-through fraction 
was collected, and a small part to be analyzed by LC-MS/MS was desalted using a Zeba Spin column (Thermo). The 
column containing TG2-bound antibodies was centrifuged at 1700 rpm for 1 min and washed three times with 1 ml 
TBS and three times with 1 ml water followed by elution three times with 200 µl 20 mM HCl. The column was 
centrifuged between each washing and elution step to ensure proper clearing of liquid. A small part of the eluate to 
be used in binding studies was immediately neutralized with NaOH and diluted in TBS. DGP-binding antibodies 
were purified from the flow-through fraction of the anti-TG2 purification step in the same way as described above, 
using streptavidin-agarose pre-incubated with 10 µM biotinylated DGP. 
 
LC-MS/MS. For liquid chromatography separation, we used an EasySpray column (C18, 2 µm beads, 100 Å, 75 μm 
inner diameter) (Thermo) capillary of 25 cm bed length and a flow rate of 0.3 μl/min. The applied solvent gradient 
was from 5% (v/v) B to 30% B over 60 min, followed by washing with 90% B for 20 min. Solvent A was aqueous 
0.1% (v/v) formic acid, and solvent B was acetonitrile with 0.1 % formic acid. The column temperature was kep t at 
60
o
C. The mass spectrometer was operated in the data-dependent mode to automatically switch between MS and 
MS/MS acquisition. Survey full scan MS spectra (from m/z 400 to 1200) were acquired in the Orbitrap  with 
resolution R = 70,000 at m/z 200 (after accumulation to a target of 3,000,000 ions in the quadrupole). The method 
used allowed sequential isolation of the most intense multiply-charged ions, up to ten, depending on signal intensity, 
for fragmentation on the HCD cell using high-energy collision dissociation at a target value of 100,000 charges or 
maximum acquisition time of 100 ms. MS/MS scans were collected at 17,500 resolution at the Orbitrap cell. Target 
ions already selected for MS/MS were dynamically excluded for 30 s. General mass spectrometry conditions were: 
electrospray voltage, 2.1 kV; no sheath and auxiliary gas flow, heated capillary temperature of 250
o
C, normalized 
HCD collision energy 25%. Ion selection threshold was set to 5e4 counts. Iso lation width of 3.0 Da was used.  
 
De novo peptide sequencing. Peptide sequences were identified using PEAKS Studio (Zhang et al., 2012) with the 
following parameters: methionine oxidation as variable modification and cysteine carbamidomethylation  as fixed 
modification, trypsin without proline restriction as enzyme option with three allowed miscleavages. Precursor and 
fragment ion error tolerances were set to 20 ppm and 0.05 Da respectively. The SPIDER (Sequence Tag 
Homology/Mutated Peptides) function in PEAKS was used to find mutations. Peptide confidence cutoff was set to 
FDR 1% and ALC (Average local confidence) 80% in order to only include peptides with high-quality MS spectra. 
We then developed an in-house Perl script which collected de novo-sequenced peptides from the PEAKS output and 
added them to the aligned protein entry in the germline database. Peptides were added N-terminally to the reference 
germline sequence in order to keep tryptic site structure. The modified germline database was then used for a regular, 
probabilistic-based peptide search, using MaxQuant (version 1.5.2.8)(Cox and Mann, 2008) for improved protein 
identification, sequence coverage and label-free quantitation. Methionine oxidation and cysteine 
carbamidomethylation were included as variable and fixed modifications, respectively. First search error window 
was set to 20 ppm and mains search error was set to 6 ppm at MS level. Trypsin without proline restriction was used 
as enzyme option with two allowed miscleavages. Minimal unique peptides were set to 1, and FDR allowed was 1% 
for peptide and protein identification. Generation of reversed sequences was selected to assign FDR rates. The levels 
of individual V-gene segments in antigen-specific and non-specific fractions were compared by t-test analysis using 
Perseus software (Tyanova et al., 2016). 
 
Isolation of TG2- and DGP-reactive PCs and sequencing of heavy chain V regions. PCs reactive with TG2 or 
DGP were stained using multimers as previously described (Di Niro et al., 2012; Steinsbø et al., 2014; Snir et al., 
2015). In short, biotinylated TG2 and DGP were multimerized using PE- and APC-labeled streptavidin, respectively, 
at a 4:1 molar ratio. Single-cell suspensions from duodenal biopsies were stained with the two multimers and the 
following cellular lineage markers: IgA-FITC (Southern Biotech), CD3- and CD14-Brilliant Violet  570 (BioLegend), 
CD19-pacific blue (BD Biosciences) and CD27-PE-Cy7 (eBioscience). PCs were defined as live, large CD14/CD3-
negative and with high expression of CD27. IgA PCs binding either TG2 or DGP were sorted into 25 µl PBS 
supplemented with 10 mM DTT and 2 U/µl RNAsin (Promega) and kept at -70°C until cDNA synthesis. For cDNA 
synthesis, 13.5 µl of sorted PCs extracts were incubated with 1.4 µM indexed IGHJ-rev primer (see primer list 
below), 0.45% (v/v) NP-40, 0.5 µl 40 U/µl and DEPC-treated water in a total volume of 25 µl at 65°C for 5 min. 
Next, we added 10 µl 5x RT buffer, 3.5 µl 100 mM DTT, 4.3 µl 10 mM dNTP-Mix (Promega), 0.7 µl 40 U/µl 
RNAsin, 0.85 µl SuperScript III (Invitrogen) and 4.5 µl DEPC-treated water, and cDNA was synthesized using the 
following temperature steps: 42°C for 10 min, 25°C for 10 min, 50°C for 60 min and 94°C for 5 min followed by 
storage at −20°C. Second-strand cDNA was synthesized using AmpliTaq Gold polymerase (Applied Biosystems) 
with indexed IGHV1-6 framework region (FR) 2 (van Dongen et al., 2003). Six random nucleotides were included in 
IGHJ and IGHV1-6 primers and were used as unique molecular identifiers (UMIs). Second-strand synthesis was 
carried out using the temperature steps: 95°C for 7.5 min, 52°C for 2 min, and 72°C for 10 minutes. Double -stranded 
cDNA was further purified using AMPure XP (Beckman Coulter) at a 1:1 ratio according to the manufacturer’s 
instructions. Next, the second part of the Illumina adapter was connected using R1 and R2 primers. PCR was 
performed using Qiagen Multiplex PCR at 95°C for 15 min, x25 (95°C for 30 seconds, 60°C for 45 seconds, 72°C 
for 90 seconds) and 72°C for 10 minutes. Primers were previously described (Snir et al., 2015). Final IGHV 
amplicon libraries were purified and concentrated using AMPure XP and further extracted from agarose gel. Paired -
end sequencing of 2x300 bp was performed using Illumina MiSeq at the Norwegian Sequencing Centre in Oslo, 
Norway (http://www.sequencing.uio.no). Raw sequencing data was processed using pRESTO (Vander Heiden et al., 
2014). Unique sequences for which at least two copies were present were further analyzed using IMGT and 
Immunoglobulin Analysis Tool (IgAT) software (Rogosch et al., 2012). 
  
Primer sequences 
 
PCR Name Sequence (5´-3´) 
1st IGHV1-FR2 GGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNNN(Index)CTGGGTGCGACAGGCCCCTGGACAA 
1st IGHV2-FR2 GGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNNN(Index)TGGATCCGTCAGCCCCCAGGGAAGG 
1st IGHV3-FR2 GGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNNN(Index)GGTCCGCCAGGCTCCAGGGAA 
1st IGHV4-FR2 GGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNNN(Index)TGGATCCGCCAGCCCCCAGGGAAGG 
1st IGHV5-FR2 GGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNNN(Index)GGGTGCGCCAGATGCCCGGGAAAGG 
1st IGHV6-FR2 GGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNNN(Index)TGGATCAGGCAGTCCCCATCGAGAG 
   
1st IGHJ-Rev ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNN(Index)CTTACCTGAGGAGACGGTGACC 
   
2nd R1 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATC 
2nd R2 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTC 
 
List of primers that were used for amplification of IGHV. IGHV1-FR2 – IGHV6-FR2 (forward) and IGHJ-Rev 
(reverse) were used for first PCR. Blue and red color indicate partial read (R)1 and  partial R2 Illumina adapters, 
respectively. Six random nucleotides (NNNNNN) were used as unique molecular identifiers (UMIs), followed by 6 
nucleotides indices and gene specific sequences. The remaining parts of Ilumina adapters were incorporated by using 
R1 and R2 primers in the second PCR.   
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